Browse > Article

CONSTRUCTION OF RECOMBINANT HSCC-1 ADENOVIRUS VECTOR FOR ORAL CANCER GENE THERAPY  

Kim, Chang-Hyen (Department of Oral and Maxillofacial Surgery, College of Medicine, The Catholic University of Korea)
Kim, Jin-Woo (Department of Obstetrics and Gynecology, College of Medicine, The Catholic University of Korea)
Kim, Myung-Jin (Department of Oral and Maxillofacial Surgery, College of Dentistry, Seoul National University)
Pyo, Sung-Woon (Department of Oral and Maxillofacial Surgery, College of Medicine, The Catholic University of Korea)
Publication Information
Maxillofacial Plastic and Reconstructive Surgery / v.27, no.2, 2005 , pp. 103-109 More about this Journal
Abstract
In spite of the ongoing advances, standard therapies for oral cancer still has some limitations in efficacy and in ability to prolong survival rate of advanced disease and result in significant functional defect and severe cosmetic deformity. Currently gene therapy using tumor suppressor gene is considered as a potent candidate for new therapeutic approaches that can improve efficacy and reduce complications. The purpose of this research is to identify the role of adenoviral vector to transfer HCCS-1 tumor suppressor gene in oral cancer cells and to find out whether there is a possibility for it to serve in the field of gene therapy. The human SCC-25 cell line was used for transfection. To determine the efficiency of the adenovirus as a gene delivery vector cell line was transduced with LacZ gene and analysed with X-gal staining. Northern blot was performed to confirm the tranfection with HSCC-1 gene and cell viability was assessed by cell cytotoxicity assay. We had successfully construct the recombinant HSCC-1 adenovirus(Ad5CMV-HCCS-1). DNA extracted from Ad5CMV-HCCS-1 revealed HCCS-1 gene is incorporated. The transduction efficiencies were over than 50% of SCC-25 cells with a MOI of 2 and over 95% with a MOI of 50. Northern blot analysis showed that a single 0.6kb mRNA transcript was expressed in Ad5CMV-HCCS-1 transduced SCC-25 cells. There was no or very low transcription HCCS-1 mRNA in wild and Ad5CMV-LacZ transduced SCC-25 cells. Cells transduced with Ad5CMV-HCCS-1 showed significant growth inhibition. By day 6, Ad5CMV-HCCS-1 treated cell count was decreased to 30% of mock-infected cells, while that of Ad5CMV-LacZ treated cells was 90% of mock-infected cells (p<0.05). Finally, these result suggest that the Ad5CMV-HCCS-1 has potential as a gene therapy tool for oral cancer.
Keywords
Oral cancer; Gene therapy; Recombinant adenovirus vector; HSCC-1 tumor suppressor gene;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Cusack JC, Jr, Tanabe KK : Cancer gene therapy. Surg Oncol Clin N Am 7 : 421, 1998   PUBMED
2 Xi S, Grandis JR : Gene therapy for the treatment of oral squamous cell carcinoma. J Dent Res 82 : 11, 2003   DOI   ScienceOn
3 Anderson MJ, Stanbridge EJ : Tumor suppressor genes studied by cell hybridization and chromosome transfer. FASEB J 7 : 826, 1993   PUBMED
4 Cai DW, Mukhopadhyay T, Liu Y, et al : Stable expression of the wild-type p53 gene in humna lung cancer after retrovirus-mediated gene transfer. Hum Gene Ther 4 : 617, 1993   DOI   ScienceOn
5 Wang J, Bucana CD, Roth JA, et al : Apoptosis induced in human osteosarcoma cells is one of the mechanims for the cytocidal effect of Ad5CMV-p53. Cancer Gene Ther 2 : 9, 1995   PUBMED
6 Rheinwald JG, Beckett MA : Tumorigenic keratinocyte lines requiring anchorage and fibroblast support cultures from human squamous cell carcinomas. Cancer Res 41 : 1657, 1981   PUBMED
7 He TC, Zhou S, DaCosta LT, et al : Simplified system for generating recombinant adenovirus. Proc Natl Acad Sci 95 : 2509, 1998
8 Kim MS, Kwon HC, Hong SI, et al : Adenovirus-mediated gene transfer of wild-type p53 results in restoration of tumor suppressor gene function in glioma cell line. J Kor Cancer Assoc20: 1026, 1998
9 Shillitoe EJ : Gene therapy for head and neck cancer. Oral Oncol 34 : 157, 1998   DOI   PUBMED   ScienceOn
10 Kim TE, Kim YW, Kim JW et al : Candidate tumor suppressor, HCCS-1, is downregulated in human cancers and induces apoptosis in cervical cancer. Int J Cancer 97 : 780, 2002   DOI   ScienceOn
11 Kim TE, Ro DY, Kim YW, et al. Adenovirus-mediated thymidine kinase gene trasnfer with exposure of ganciclovir to uterine cervical cancer cell. Kor J Gynecol Oncol Colposcopy 14: 195, 2003
12 Daqing L, Ling D, Paul F, et al : Variability of adenovirus receptor density influences gene transfer efficiency and therapeutic response in head and neck cancer. Clin Cancer Res 5 : 4175, 1999   PUBMED
13 Clayman GL, Frank DK, Bruso PA, et al : Adenovirusmediated wild-type p53 gene transfer as a surgical adjuvant in advanced head and neck cancers. Clin Cancer Res 5 : 1715, 1999   PUBMED
14 Schrijvers D, Johnson J, Jiminez U, et al : Phase III trial of modulation of cisplatin/fluorouracil chemotherapy by interferon alfa-2b in patients with recurrent or metastatic head and neck cancer. Head and Neck Interferon Cooperative Study group. J Clin Oncol 16 : 1054, 1998   PUBMED
15 Graham FL, Smiley J : Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J Gen Virol 36 : 59, 1977   DOI   ScienceOn
16 Zhang WW, Fang X, Mazur W, et al : High-efficiency gene transfer and high-level expression of wild-type p53 in human lung cancer cells mediated by recombinant adenovirus. Cancer Gene Ther 1 : 5, 1994   PUBMED
17 Takenouchi, T, Munetaka E : Trophic effects of substance P and beta-amyloid peptide on dibutyryl cyclic AMP-differentiated human leukemic (HL-60) cells. Life Sci 56 : 479, 1995   DOI   ScienceOn
18 Wolff JA, Trubetskoy VS : The Cambrian period of nonviral gene delivery (news). Nat Biotechnol 16 : 421, 1998   DOI   ScienceOn
19 Cho SD, Hwang SJ, Park HR, et al. Development of gene therapy strategy using plasmid and adenovirus in cervical cancer treatment. J Kor Obstet Gynecol 42: 2019, 1999
20 McGroy WJ, Bautista DS, Graham FL : A simple techniques for the rescue of early region 1 mutations into infectious human adenovirus type 5. Virology 163 : 614, 1988   DOI   ScienceOn
21 Nemunaitis J, Ganly I, Khuri F, et al : Seletive replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer; a phase II trial. Cancer Res 60 : 6359, 2000   PUBMED
22 Fukuhara H, Hayashi Y, Yamamoto N, et al. Improvement of transduction efficiency of recombinant adenovirus vector conjugated with cationic liposome for human oral squamous cell carcinoma cell line. Oral Oncol 39 : 601, 2003   DOI   ScienceOn
23 Schwartz GJ, Mehta RH, Wenig BL, et al : Salvage management for recurrent squamous cell carcinoma of the oral cavity. Head Neck 22 : 34, 2000   DOI   ScienceOn
24 Robbins PD, Tahara H, Ghivizzani SC : Viral vectors for gene therapy. Trends Biotechnol 16 : 35, 1998   DOI   ScienceOn
25 Shillitoe EJ, Laypeyre JN, Adler-Storthz K : Gene therapy-it's potential in the management of oral cancer. Oral Oncol 3 : 957, 1996
26 Liu TJ, Zhang WW, Taylor DL, et al : Growth suppression of human head and neck cancer cells by the introduction of a wild-type p53 gene via a recombinant adenovirus. Cancer Res 54 : 3662, 1994   PUBMED
27 Zhang WW : Development and application of adenoviral vectors for gene therapy of cancer. Cancer Gene Ther 6 : 113, 1999   DOI   PUBMED   ScienceOn
28 Hamada K, Sakaue M, Alemany R, et al : Adenovirus transfer of HPV 16 E6/E7 antisense RNA to human cervical cancer cells. Gyne Oncol 63 : 219, 1996   DOI   ScienceOn
29 Chirmule N, Propert K, Magosin S, et al : Immune responses to adenovirus and adeno-associated virus in humans. Cancer Gene Ther 6 : 1574, 1999
30 Sun LM, Leung SW, Su CY : The relapse patterns and outcome of postoperative recurrent tongue cancer. J Oral Maxillofac Surg 55 : 827, 1997   DOI   ScienceOn